Contact this trialFirst, we need to learn more about you.
CDK 4/6 Inhibitor
G1T38 +1 More for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is investigating whether a new drug, G1T38, is safe and effective when combined with osimertinib for patients with EGFR mutation-positive metastatic non-small cell lung cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.